Orexigen Therapeutics (OREX) Stock Continues to Rise as EU Reviews Contrave Drug

NEW YORK (TheStreet) -- Shares of Orexigen Therapeutics Inc. (OREX)  continue to soar, up 34.81% to $5.19 Monday afternoon, after the company said the European Union review of Contrave, its weight loss drug for adults, is progressing on schedule.

In September, Orexigen received U.S. approval for Contrave from the Food and Drug Administration.

The La Jolla, CA-based company reported better than expected third quarter results this morning with earnings of $11.3 million, or 9 cents per share, surpassing analysts' estimates of a loss of 13 cents per share.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

The drug developer for obesity posted revenue of $30.9 million for the quarter, significantly higher versus the consensus estimate of $8.93 million.

Separately, TheStreet Ratings team rates OREXIGEN THERAPEUTICS INC as a Sell with a ratings score of D-. TheStreet Ratings Team has this to say about their recommendation:

"We rate OREXIGEN THERAPEUTICS INC (OREX) a SELL. This is driven by some concerns, which we believe should have a greater impact than any strengths, and could make it more difficult for investors to achieve positive results compared to most of the stocks we cover. The company's weaknesses can be seen in multiple areas, such as its unimpressive growth in net income, disappointing return on equity, weak operating cash flow, generally high debt management risk and generally disappointing historical performance in the stock itself."

OREX Chart OREX data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Apple and GE Switch Roles; Musk's Super Control of Tesla Explained -- ICYMI

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Trump May Be More to Blame For Higher Oil Prices Than OPEC

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Dow Falls Over 200 Points as Apple's Slump Offsets Gains in General Electric

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

Week Ahead: Major Earnings on Tap as Wall Street Readies for Geopolitical Moves

3 Hot Reads From TheStreet's Top Premium Columnists

3 Hot Reads From TheStreet's Top Premium Columnists